PRECISION BIOSCIENCES INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
PRECISION BIOSCIENCES INC (DTIL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -41.20% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-26
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was -41.20%, a 516.16% decline from fiscal 2023.
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 9.90%, a 191.18% increase from fiscal 2022.
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 3.40%, a 80.12% decline from fiscal 2021.
- PRECISION BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 17.10%, a 171.43% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | -41.20% 10-K · filed 2025-03-26 |
| 2023-12-31 | 9.90% 10-K · filed 2025-03-26 |
| 2022-12-31 | 3.40% 10-K · filed 2024-03-27 |
| 2021-12-31 | 17.10% 10-K · filed 2023-03-09 |
| 2020-12-31 | 6.30% 10-K · filed 2022-03-15 |
| 2019-12-31 | 5.10% 10-K · filed 2021-03-18 |
| 2018-12-31 | 4.20% 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |